Julian Mclain, MD
Hematology/Oncology · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mclain’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$19,717
Medicare paid this office $19,717 for 61 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 20 | $6,495 | $171 |
| New patient visit (60+ min) | 20 | $4,133 | $207 |
| New patient visit (45+ min) | 22 | $3,466 | $158 |
| Return visit (30+ min) | 18 | $2,204 | $122 |
Who their Medicare patients are
61 Original Medicare patients in 2024. Average age 78 · Women 53% · Health risk score 1.29. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Chronic kidney disease 26% · Cancer 26% · Diabetes 23% · Coronary heart disease 23% · Atrial fibrillation 20%.
The office billed $67,053, Medicare allowed $24,748 and paid $19,717; for 135 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$0 in 2023
Medicaid paid $0 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit | 12 | $0 |
| 2023 | 12 | 1 | 12 | $0 |
Drugs they prescribed that Part D paid
$232,692
Pharmacies billed $232,692 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
123 generic and fewer than 11 brand-name prescriptions · $232,692 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Anastrozole | 24 | $191 | $8 |
| Ondansetron | 15 | $112 | $7 |
Year by year
| 2024 | 147 | 48 | None | None | $232,692 |
| 2023 | 162 | 48 | None | None | $235,879 |
| 2022 | 90 | 32 | 13% (12) | None | $35,947 |
| 2021 | 257 | 49 | None | None | $41,108 |
| 2020 | 199 | 47 | None | None | $87,645 |
| 2019 | 27 | None | 0% (0) | None | $70,160 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Abiraterone Acetate | 12 | $62,772 | $5,231 |
| Anastrozole | 14 | $167 | $12 |
| Ondansetron | 12 | $127 | $11 |
2021: 5 drugs
| Atorvastatin | 19 | $544 | $29 |
| Diclofenac | 15 | $426 | $28 |
| Amlodipine Besylate | 17 | $203 | $12 |
| Benazepril | 11 | $110 | $10 |
| Alendronate | 11 | $88 | $8 |
2020: 3 drugs
| Diclofenac | 18 | $532 | $30 |
| Atorvastatin | 14 | $194 | $14 |
| Amlodipine Besylate | 11 | $96 | $9 |
Money from drug and device companies
$2,670 in 2025
| 2025 | 33 | 91 | None | $2,670 |
| 2024 | 23 | 45 | None | $1,426 |
| 2023 | 17 | 60 | None | $2,032 |
| 2022 | 14 | 54 | None | $1,900 |
| 2021 | 10 | 16 | None | $930 |
| 2020 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $446 | 12 payments
|
| Janssen Biotech | Tecvayli | $233 | 8 payments
|
| Novartis Pharmaceuticals | Kisqali | $225 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $138 | 6 payments
|
| Celgene | Opdivo | $126 | 3 payments
|
| Gilead Sciences | Trodelvy | $110 | 5 payments
|
See all 90 published payments
| Agios Pharmaceuticals | Meals · 2025-12-22 | Pyrukynd | $29 |
| Pfizer | Meals · 2025-12-12 | Elrexfio | $25 |
| Abbvie | Meals · 2025-12-11 | Epkinly | $41 |
| Rigel Pharmaceuticals | Meals · 2025-12-11 | Tavalisse | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-08 | Opdivo | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | Lynparza | $17 |
| Janssen Biotech | Meals · 2025-12-02 | Tecvayli | $30 |
| Janssen Biotech | Meals · 2025-12-01 | Tecvayli | $2 |
| Novartis Pharmaceuticals | Meals · 2025-12-01 | Kisqali | $34 |
| Adc Therapeutics America | Meals · 2025-11-21 | Zynlonta | $35 |
| Abbvie | Meals · 2025-11-20 | Imbruvica | $28 |
| Rigel Pharmaceuticals | Meals · 2025-11-19 | Tavalisse | $25 |
| GlaxoSmithKline | Meals · 2025-11-11 | Blenrep | $23 |
| Daiichi Sankyo | Meals · 2025-11-10 | Datroway | $23 |
| Abbvie | Meals · 2025-11-04 | Venclexta | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Opdivo | $2 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Opdivo | $30 |
| BeOne Medicines USA | Meals · 2025-10-28 | Brukinsa | $30 |
| Novartis Pharmaceuticals | Meals · 2025-10-27 | Kisqali | $33 |
| Genzyme | Meals · 2025-10-23 | Ayvakit | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-21 | Opdivo | $35 |
| Incyte | Meals · 2025-10-20 | Monjuvi | $25 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Pluvicto | $24 |
| Novartis Pharmaceuticals | Meals · 2025-10-13 | Kisqali | $34 |
| Gilead Sciences | Meals · 2025-10-08 | Trodelvy | $20 |
| Novocure | Meals · 2025-10-07 | Optune Gio | $32 |
| Pfizer | Meals · 2025-09-30 | Xtandi | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-09-29 | Libtayo | $40 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-26 | Enhertu | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Calquence | $29 |
| Agios Pharmaceuticals | Meals · 2025-09-22 | Pyrukynd | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-09 | Enhertu | $29 |
| Adc Therapeutics America | Meals · 2025-09-08 | Zynlonta | $39 |
| Merck Sharp & Dohme | Meals · 2025-09-02 | Keytruda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-26 | Enhertu | $29 |
| Novocure | Meals · 2025-08-25 | Optune Lua (Novottf-200t) | $17 |
| Kite Pharma | Meals · 2025-08-19 | Yescarta | $15 |
| Kite Pharma | Meals · 2025-08-19 | Yescarta | $23 |
| Astellas Pharma US | Meals · 2025-08-18 | Xtandi | $24 |
| Merck Sharp & Dohme | Meals · 2025-08-12 | Keytruda | $27 |
| Janssen Biotech | Meals · 2025-08-05 | Erleada | $43 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-04 | Opdivo | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | Tagrisso | $37 |
| Tempus AI | Meals · 2025-07-24 | Xt Cdx | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-21 | None | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Calquence | $20 |
| Janssen Biotech | Meals · 2025-07-15 | Carvykti | $40 |
| Merck Sharp & Dohme | Meals · 2025-07-08 | Keytruda | $31 |
| Caris MPI | Meals · 2025-07-01 | Mi Cancer Seek | $21 |
| Janssen Biotech | Meals · 2025-06-30 | Tecvayli | $37 |
| Janssen Biotech | Meals · 2025-06-29 | Tecvayli | $2 |
| Gilead Sciences | Meals · 2025-06-26 | Trodelvy | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-23 | Fruzaqla | $34 |
| Novartis Pharmaceuticals | Meals · 2025-06-16 | Kisqali | $33 |
| Array Biopharma | Meals · 2025-06-10 | Xalkori | $30 |
| Puma Biotechnology | Meals · 2025-06-09 | Nerlynx | $26 |
| Jazz Pharmaceuticals | Meals · 2025-06-03 | Ziihera | $39 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-29 | Calquence | $27 |
| Celgene | Meals · 2025-05-27 | Opdivo | $28 |
| Adaptive Biotechnologies | Meals · 2025-05-22 | Clonoseq | $30 |
| Geron | Meals · 2025-05-20 | Rytelo | $28 |
| Janssen Biotech | Meals · 2025-05-19 | Erleada | $39 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-13 | Enhertu | $125 |
| Daiichi Sankyo | Meals · 2025-05-12 | Enhertu | $23 |
| Novocure | Meals · 2025-05-12 | Optune Lua (Novottf-200t) | $16 |
| Astellas Pharma US | Meals · 2025-05-06 | Xtandi | $23 |
| Celgene | Meals · 2025-05-05 | Opdivo | $65 |
| Regeneron Healthcare Solutions | Meals · 2025-04-28 | Libtayo | $38 |
| Tempus AI | Meals · 2025-04-23 | Xt Cdx | $36 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Kisqali | $34 |
| Lilly USA | Meals · 2025-04-21 | Verzenio | $33 |
| Agios Pharmaceuticals | Meals · 2025-04-14 | Pyrukynd | $37 |
| Kite Pharma | Meals · 2025-04-09 | Yescarta | $28 |
| Taiho Oncology | Meals · 2025-04-08 | Lonsurf | $45 |
| Astellas Pharma US | Meals · 2025-03-25 | Vyloy | $26 |
| Aadi Bioscience | Meals · 2025-03-24 | Fyarro | $21 |
| Astellas Pharma US | Meals · 2025-03-08 | Xtandi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-03 | Enhertu | $33 |
| Novartis Pharmaceuticals | Meals · 2025-02-25 | Pluvicto | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Calquence | $30 |
| Gilead Sciences | Meals · 2025-02-20 | Trodelvy | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Enhertu | $34 |
| Incyte | Meals · 2025-02-18 | Monjuvi | $24 |
| GlaxoSmithKline | Meals · 2025-02-13 | Ojjaara | $28 |
| Janssen Biotech | Meals · 2025-02-12 | Tecvayli | $40 |
| Gilead Sciences | Meals · 2025-02-11 | Trodelvy | $22 |
| Celgene | Meals · 2025-02-10 | Opdivo | $34 |
| Incyte | Meals · 2025-02-03 | Jakafi | $26 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-12 | Nubeqa | $22 |
| Gilead Sciences | Meals · 2025-01-06 | Trodelvy | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $1,426
| AstraZeneca Pharmaceuticals LP | Enhertu | $228 | 4 payments
|
| EMD Serono | None | $160 | 4 payments
|
| Celgene | Reblozyl | $135 | 6 payments
|
| Blueprint Medicines | None | $118 | 1 payment
|
| Incyte | Pemazyre | $74 | 3 payments
|
| Janssen Biotech | Rybrevant | $64 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $62 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $60 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $59 | 2 payments
|
| Daiichi Sankyo | Enhertu | $55 | 2 payments
|
| Servier Pharmaceuticals | Asparlas | $48 | 2 payments
|
| Abbvie | Venclexta | $46 | 2 payments
|
| BeiGene USA | Brukinsa | $43 | 2 payments
|
| Genzyme | Sarclisa | $42 | 2 payments
|
| Agios Pharmaceuticals | Pyrukynd | $33 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $32 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $27 | 1 payment
|
| Coherus Biosciences | Udenyca | $27 | 1 payment
|
| Eisai | Lenvima | $24 | 1 payment
|
| Exelixis | Cabometyx | $24 | 1 payment
|
| Genentech USA | Alecensa | $23 | 1 payment
|
| Lilly USA | Verzenio | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $19 | 1 payment
|
2023: $2,032
| Genzyme | Sarclisa | $473 | 10 payments
|
| Seagen | Adcetris | $340 | 4 payments
|
| Celgene | Pomalyst | $247 | 14 payments
|
| Abbvie | Venclexta | $228 | 10 payments
|
| Karyopharm Therapeutics | Xpovio | $136 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $134 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Pomalyst | $99 | 1 payment
|
| Puma Biotechnology | Nerlynx | $57 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $54 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $53 | 2 payments
|
| Incyte | Jakafi | $52 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $43 | 2 payments
|
| Daiichi Sankyo | Enhertu | $29 | 1 payment
|
| Amgen | Kyprolis | $26 | 1 payment
|
| Servier Pharmaceuticals | None | $23 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $23 | 1 payment
|
| EMD Serono | Bavencio | $14 | 1 payment
|
2022: $1,900
| Celgene | Pomalyst | $412 | 23 payments
|
| Jazz Pharmaceuticals | Defitelio | $261 | 2 payments
|
| Seagen | Padcev | $251 | 2 payments
|
| Genzyme | Sarclisa | $215 | 5 payments
|
| Incyte | Jakafi | $203 | 6 payments
|
| Amgen | Nplate | $141 | 5 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Pomalyst | $88 | 1 payment
|
| Abbvie | Venclexta | $72 | 3 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $40 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $32 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $23 | 1 payment
|
| Gilead Sciences | Trodelvy | $16 | 1 payment
|
2021: $930
| Genzyme | Sarclisa | $180 | 4 payments
|
| Jazz Pharmaceuticals | Rylaze | $129 | 1 payment
|
| Celgene | Pomalyst | $123 | 2 payments
|
| Seagen | Adcetris | $122 | 1 payment
|
| Amgen | Blincyto | $120 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $117 | 1 payment
|
| Incyte | Jakafi | $54 | 2 payments
|
| AbbVie | Venclexta | $45 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $23 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $17 | 1 payment
|
2020: $22
| Incyte | Jakafi | $22 | 1 payment
|
Professional record
- NPI
- 1063916591
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2018-03-20
- NPI last updated
- 2024-08-05
- NPI record certified
- 2024-08-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1200 N State Street, Los Angeles, CA, 90033